Results 81 to 90 of about 13,301,732 (374)

Genetic Variants of Hemophilia B. [PDF]

Thrombosis and Haemostasis, 1977
The purpose of this report is to describe genetic variants of hemophilia B. Most variants have been distinguished on the basis of clinical severity of their disease, as well as immunological, functional, and biochemical characterization of the Factor IX molecule.
H.R. Roberts, K. S. Chung, J.C. Goldsmith   +2 more
openaire   +1 more source

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman, Marjon H. Cnossen, Ron A.A. Mathot, on behalf of the OPTI‐CLOT study group and SYMPHONY consortium, S. H. Reitsma   +4 more
wiley   +1 more source

ORAL TREATMENT OF HEMOPHILIA [PDF]

, 2007
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome.
Alpan, Oral, Kamala, Tirumalai, Matzinger, Polly, Velander, William Hugold   +3 more
core   +1 more source

Origin of Swedish hemophilia B mutations [PDF]

Journal of Thrombosis and Haemostasis, 2013
More than 1100 mutations that cause hemophilia B (HB) have been identified. At the same time, specific F9 mutations are present at high frequencies in certain populations, which raise questions about the origin of HB mutations.To describe the mutation spectrum of all HB families in Sweden and investigate if mutations appearing in several families are ...
Christina Lind-Halldén, Christer Halldén, Annika Mårtensson, Daniel Nilsson, Daniel Nilsson, Torbjörn Säll, Rolf Ljung, Annika C. Lidén   +7 more
openaire   +3 more sources

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source

Why should hemophilia B be milder than hemophilia A?

Haematologica, 2016
We read with interest the report by Melchiorre et al .[1][1] on the milder clinical parameters in hemophilia B as compared to hemophilia A. The single most important factor which contributes to the severity of hemophilia is the nature of mutations.
Shrimati Shetty, Kanjaksha Ghosh
openaire   +4 more sources

Laparoscopic nephrectomy in a hemophilia B patient [PDF]

Central European Journal of Urology, 2016
Surgery in patients with hemophilia is a serious challenge. It requires a comprehensive approach, as well as careful postoperative monitoring. We present here the first case of a transperitoneal laparoscopic radical nephrectomy (TLRN) for renal cell carcinoma, of the clear-cell type, performed in a hemophilia B patient.
Gajda, Slawomir, Szopiński, Tomasz, Szczepanik, Andrzej B., Sosnowski, Roman, Szczepanik, Anna M.   +4 more
openaire   +3 more sources

Surgical and Medical Co‐Management in an 82‐Year‐Old Patient With Hemophilia a Undergoing Pancreaticoduodenectomy

Health Care Science, EarlyView.
The surgical and medical co‐management (SMC) team integrates internists and surgeons to improve perioperative planning to minimize complications and promote recovery. SMCs team implemented various perioperative optimization strategies for the patient to prevent complications and enhance satisfaction.
Wenning Lu, Chaoyang Liu, Jing He, Rui Cheng   +3 more
wiley   +1 more source

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Blood Advances, 2018
: Data are needed on minimal factor activity (FA) levels required to prevent bleeding in hemophilia. We aimed to evaluate associations between hemophilia type and FA level and joint bleeding and orthopedic procedures using longitudinal data.
J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A. Konkle, Marshall A. Mazepa   +4 more
doaj  

Pharmacokinetic Study of Recombinant Human Factor IX in Previously Treated Patients with Hemophilia B in Taiwan

Journal of the Formosan Medical Association, 2007
The pharmacokinetic (PK) study of recombinant human factor IX (rFIX) has been done in patients with hemophilia B in areas other than Taiwan. However, wide patient-related variability in recovery is noted and there is no PK study of rFIX in Taiwanese ...
Hsiu-Hao Chang, Yung-Li Yang, Mei-Hua Hung, Woei Tsay, Ming-Ching Shen   +4 more
doaj   +1 more source